Amgen CFO Peter Griffith to retire; Thomas Dittrich named CFO

Key highlights
  • Amgen CFO Peter Griffith will retire; Thomas Dittrich returns July 1 as EVP and assumes CFO duties on Sept 1, 2026.
  • Griffith will remain through January 2027 to support the transition.
  • Dittrich, with 30+ years of international finance experience, previously served as CFO at Galderma, Shire and Sulzer and will oversee Amgen's financial operations.

Leadership change

Peter Griffith, Amgen's executive vice president and chief financial officer since 2020, has announced his retirement; Thomas Dittrich will return to Amgen as executive vice president on July 1 and succeed Griffith as chief financial officer effective September 1, 2026.

Transition plan

Griffith will remain with the company through January 2027 to support a seamless transition and hand over financial responsibilities to Dittrich.

Successor background

Dittrich brings more than 30 years of international finance leadership, previously held senior finance roles at Amgen, served most recently as CFO of Galderma, and earlier as CFO at Shire and Sulzer; he will oversee all aspects of Amgen's financial operations.

Outgoing CFO's impact

During his tenure Griffith strengthened Amgen's financial foundation, supported disciplined capital allocation and helped advance the company's long-term growth strategy.

Source: Amgen

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

7 June 2026
Amgen: Repatha (evolocumab) cuts first major CV events 29% in high‑risk diabetes subgroup

VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.

4 May 2026
Amgen invests $300M more in U.S. manufacturing, nearly $2B over past year

Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience

22 April 2026
Amgen EVP & CTO David M. Reese to retire

Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.

28 March 2026
Amgen: Repatha cuts first major cardiovascular events 31% in high‑risk patients without significant atherosclerosis

VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.